PD-1/PD-L1 axis blockades demonstrate noteworthy benefits in treating multiple types of cancer including melanoma, head and neck cancer, bladder cancer, lung cancer and triple negative breast cancer with manageable adverse effects (6–10). The gene discussed is CD274; the disease is cancer.